N4 Pharma PLC Exercise of Warrants and Total Voting Rights (3231H)
June 06 2017 - 9:06AM
UK Regulatory
TIDMN4P
RNS Number : 3231H
N4 Pharma PLC
06 June 2017
6 June 2017
N4 Pharma Plc
("N4 Pharma" or the "Company")
Exercise of Warrants and Total Voting Rights
The Company announces that it has received exercise notices for
the exercise of warrants over ordinary shares of 0.4p each at an
exercise price of 8 pence per warrant ("New Ordinary Shares").
Application has been made for admission of 1,187,500 New Ordinary
Shares to trading on AIM ("Admission") and it is expected that
Admission will take place and that trading will commence on AIM at
8.00 a.m. on 12 June 2017.
Following Admission, there will be a total of 74,714,285
ordinary shares in issue. Shareholders should use the figure of
74,714,285 as the denominator for the calculations by which they
will determine if they are required to notify their interest in, or
a change to their interest in the Company, under the FCA's
Disclosure and Transparency Rules.
Enquiries:
N4 Pharma
CEO, Nigel Theobald Via Alma PR
Stockdale Securities
Tom Griffiths Tel: +44(0)207 601 6100
Beaufort Securities
Elliot Hance Tel: +44(0)207 382 8300
Alma PR
Josh Royston Tel: +44(0)778 090 1979
Robyn Fisher Tel: +44(0)754 070 6191
About N4 Pharma
N4 Pharma was formed in 2014 by Nigel Theobald, the former Chief
Executive of AIM quoted Oxford Pharmascience Group plc. It is a
specialist pharmaceutical company which reformulates existing drugs
and vaccines to improve their performance.
N4 Pharma's reformulation work falls under two divisions:
-- generic, already commercialised, drugs; and
-- delivery of novel and existing vaccines.
N4 Pharma has identified a number of established drugs that
could be improved upon through its reformulation techniques. N4
Pharma's most advanced reformulation is for sildenafil, widely
marketed as Viagra, where N4 Pharma is seeking to improve the speed
at which the drug takes effect whilst also extending its duration
of action.
N4 Pharma's reformulation approach should take approximately
three years to obtain regulatory approval as opposed to the
traditional process for new drugs of on average ten years. The cost
and risk profile of this model is also significantly less than the
traditional process. N4 Pharma's business model is to take
reformulated drugs from its portfolio through to the stage where it
will license its newly reformulated drugs to pharmaceutical
companies to commercialise them. N4 Pharma's revenues should be
derived from up front milestone and royalty payments associated
with the licence.
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCGMGGVDVFGNZM
(END) Dow Jones Newswires
June 06, 2017 10:06 ET (14:06 GMT)
N4 Pharma (LSE:N4P)
Historical Stock Chart
From Apr 2024 to May 2024
N4 Pharma (LSE:N4P)
Historical Stock Chart
From May 2023 to May 2024